Immunological Mechanisms in Cancer

肿瘤发生的免疫机制 癌症免疫机制项目由来自六个学术机构的十九名研究人员组成。 部门 IMC计划的主要目标是1）创建一个强大的，智力和高度互动的 科学环境中，免疫系统的功能，因为它涉及到癌症问题， 进行有效和有效的调查; 2）通过方案内和方案间 合作，将从这些研究中获得的知识转化为方法的发展 用于癌症的预防、诊断和治疗。 教师的利益是多种多样的，但该计划是由四个主要主题统一：1）提高我们的 了解造血系统恶性肿瘤发生的分子和细胞基础; 2） 阐明免疫系统对肿瘤抗原识别和应答的性质，从而 支持癌症免疫治疗方法的发展; 3）研究病毒在癌症中的作用， 癌症和癌症疗法的发展;以及4）改善骨髓 用于治疗造血系统恶性肿瘤的移植方法。 在19个项目成员中，有18个是通过同行评审的奖项获得资助的。当前NCI 对该项目的同行评审支持总额分别约为180万美元和820万美元。在 在上一个资助期内，项目成员发表了150篇与癌症相关的论文，分别占14%和20%。 这两个项目分别是方案内和方案间合作的结果。之间的合作 Kimmel癌症中心的这一项目和其他项目的成员为制作 试剂和临床前模型分析，用于测试已导致临床试验的新疗法。 该计划成员提供的专业知识和见解对中心越来越重要 用于定义宿主-肿瘤相互作用的功能和分子方面。进一步发展 该计划的主要研究领域是肿瘤免疫学和树突细胞免疫生物学。

IMMUNOLOGICAL MECHANISMS IN CANCER PROGRAM The Immunological Mechanisms in Cancer Program comprises nineteen investigators from six academic departments. The primary objectives of the IMC Program are 1) to create a strong, intellectual and highly interactive scientific environment in which the functioning of the immune system as it relates to the cancer problem can be imaginatively and efficiently investigated; and 2) to foster, through intra- and inter-programmatic collaboration, the translation of the knowledge gained from these studies to the development of approaches for the prevention, diagnosis and treatment of cancer. The interests of the faculty are varied but the program is unified by four main themes: 1) to improve our understanding of the molecular and cellular basis for the development hematopoietic malignancies; 2) to elucidate the nature of tumor antigen recognition and response to tumors by the immune system, thereby supporting development of immunotherapeutic approaches to cancer; 3) to investigate the role of viruses in the development of cancer and cancer therapies; and 4) to create improvements in bone marrow transplantation approaches for the treatment of hematopoietic malignancies. Of the nineteen program members, eighteen have been funded through peer-reviewed awards. Current NCI and total peer review support for this program total approximately 1.8 and 8.2 million dollars, respectively. In the previous funding period, program members published 150 cancer-relevant papers, 14 and 20 percent of which resulted from intra, and inter-programmatic collaborations, respectively. Collaborations between members of this and other programs in the Kimmel Cancer Center have contributed to the production of reagents and analysis of preclinical models for testing novel therapies that have resulted in clinical trials. The expertise and the insight provided by members of the program is of increasing importance to the center for the definition of both functional and molecular aspects of the host-tumor interaction. Further development of the program is planned in the areas of tumor immunology and the immunobiology of dendritic cells.